nodes	percent_of_prediction	percent_of_DWPC	metapath
Sparfloxacin—TOP2A—Valrubicin—urinary bladder cancer	0.479	0.581	CbGbCtD
Sparfloxacin—TOP2A—Epirubicin—urinary bladder cancer	0.0725	0.088	CbGbCtD
Sparfloxacin—TOP2A—Etoposide—urinary bladder cancer	0.0565	0.0685	CbGbCtD
Sparfloxacin—TOP2A—Doxorubicin—urinary bladder cancer	0.0385	0.0467	CbGbCtD
Sparfloxacin—ABCB1—Mitomycin—urinary bladder cancer	0.0368	0.0446	CbGbCtD
Sparfloxacin—ABCC2—Carboplatin—urinary bladder cancer	0.0276	0.0335	CbGbCtD
Sparfloxacin—ABCC2—Cisplatin—urinary bladder cancer	0.0236	0.0286	CbGbCtD
Sparfloxacin—ABCC2—Etoposide—urinary bladder cancer	0.0232	0.0281	CbGbCtD
Sparfloxacin—ABCC2—Doxorubicin—urinary bladder cancer	0.0158	0.0192	CbGbCtD
Sparfloxacin—ABCC2—Methotrexate—urinary bladder cancer	0.0153	0.0186	CbGbCtD
Sparfloxacin—ABCB1—Gemcitabine—urinary bladder cancer	0.0106	0.0128	CbGbCtD
Sparfloxacin—ABCB1—Cisplatin—urinary bladder cancer	0.00769	0.00933	CbGbCtD
Sparfloxacin—ABCB1—Etoposide—urinary bladder cancer	0.00756	0.00917	CbGbCtD
Sparfloxacin—ABCB1—Doxorubicin—urinary bladder cancer	0.00515	0.00625	CbGbCtD
Sparfloxacin—ABCB1—Methotrexate—urinary bladder cancer	0.00499	0.00606	CbGbCtD
Sparfloxacin—ABCC2—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00342	0.143	CbGpPWpGaD
Sparfloxacin—ABCB1—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00161	0.0672	CbGpPWpGaD
Sparfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—KRT5—urinary bladder cancer	0.00118	0.0495	CbGpPWpGaD
Sparfloxacin—TOP2A—prostate gland—urinary bladder cancer	0.00111	0.138	CbGeAlD
Sparfloxacin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000966	0.0404	CbGpPWpGaD
Sparfloxacin—ABCC2—prostate gland—urinary bladder cancer	0.000759	0.094	CbGeAlD
Sparfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—TP63—urinary bladder cancer	0.000717	0.03	CbGpPWpGaD
Sparfloxacin—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.000694	0.029	CbGpPWpGaD
Sparfloxacin—TOP2A—G0 and Early G1—CCNE1—urinary bladder cancer	0.000597	0.025	CbGpPWpGaD
Sparfloxacin—SLC22A5—prostate gland—urinary bladder cancer	0.000588	0.0729	CbGeAlD
Sparfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—IGFBP3—urinary bladder cancer	0.000563	0.0236	CbGpPWpGaD
Sparfloxacin—TOP2A—vagina—urinary bladder cancer	0.000548	0.0679	CbGeAlD
Sparfloxacin—TOP2A—Idarubicin—Valrubicin—urinary bladder cancer	0.000536	0.125	CbGdCrCtD
Sparfloxacin—TOP2A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000536	0.125	CbGdCrCtD
Sparfloxacin—TOP2A—Epirubicin—Valrubicin—urinary bladder cancer	0.000536	0.125	CbGdCrCtD
Sparfloxacin—TOP2A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000536	0.125	CbGdCrCtD
Sparfloxacin—ABCC2—renal system—urinary bladder cancer	0.000517	0.0641	CbGeAlD
Sparfloxacin—SLC22A5—seminal vesicle—urinary bladder cancer	0.000497	0.0616	CbGeAlD
Sparfloxacin—ABCC2—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000495	0.0207	CbGpPWpGaD
Sparfloxacin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000454	0.019	CbGpPWpGaD
Sparfloxacin—ABCC2—female reproductive system—urinary bladder cancer	0.000414	0.0513	CbGeAlD
Sparfloxacin—SLC22A5—renal system—urinary bladder cancer	0.000401	0.0497	CbGeAlD
Sparfloxacin—SLC22A5—urethra—urinary bladder cancer	0.000394	0.0488	CbGeAlD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—RRM2—urinary bladder cancer	0.000374	0.0156	CbGpPWpGaD
Sparfloxacin—TOP2A—Podofilox—Etoposide—urinary bladder cancer	0.000358	0.0835	CbGdCrCtD
Sparfloxacin—TOP2A—Teniposide—Etoposide—urinary bladder cancer	0.000358	0.0835	CbGdCrCtD
Sparfloxacin—TOP2A—lymph node—urinary bladder cancer	0.000354	0.0439	CbGeAlD
Sparfloxacin—TOP2A—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.000344	0.0144	CbGpPWpGaD
Sparfloxacin—ABCC2—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000335	0.014	CbGpPWpGaD
Sparfloxacin—SLC22A5—female reproductive system—urinary bladder cancer	0.000321	0.0398	CbGeAlD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—SMC1A—urinary bladder cancer	0.000318	0.0133	CbGpPWpGaD
Sparfloxacin—SLC22A5—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000315	0.0132	CbGpPWpGaD
Sparfloxacin—SLC22A5—vagina—urinary bladder cancer	0.00029	0.036	CbGeAlD
Sparfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—ATM—urinary bladder cancer	0.000277	0.0116	CbGpPWpGaD
Sparfloxacin—ABCB1—prostate gland—urinary bladder cancer	0.000273	0.0338	CbGeAlD
Sparfloxacin—TOP2A—Cell Cycle—SMC1B—urinary bladder cancer	0.00027	0.0113	CbGpPWpGaD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—RRM2—urinary bladder cancer	0.000263	0.011	CbGpPWpGaD
Sparfloxacin—ABCC2—lymph node—urinary bladder cancer	0.000242	0.03	CbGeAlD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000242	0.0101	CbGpPWpGaD
Sparfloxacin—ABCB1—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000233	0.00975	CbGpPWpGaD
Sparfloxacin—ABCB1—seminal vesicle—urinary bladder cancer	0.000231	0.0286	CbGeAlD
Sparfloxacin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000228	0.00952	CbGpPWpGaD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CCNE1—urinary bladder cancer	0.00022	0.00922	CbGpPWpGaD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—urinary bladder cancer	0.000216	0.00905	CbGpPWpGaD
Sparfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—urinary bladder cancer	0.000211	0.00883	CbGpPWpGaD
Sparfloxacin—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	0.000201	0.047	CbGdCrCtD
Sparfloxacin—ABCB1—epithelium—urinary bladder cancer	0.0002	0.0249	CbGeAlD
Sparfloxacin—TOP2A—Gastric Cancer Network 2—MYC—urinary bladder cancer	0.000199	0.00835	CbGpPWpGaD
Sparfloxacin—TOP2A—Gastric Cancer Network 2—EGFR—urinary bladder cancer	0.000195	0.00816	CbGpPWpGaD
Sparfloxacin—SLC22A5—lymph node—urinary bladder cancer	0.000188	0.0233	CbGeAlD
Sparfloxacin—TOP2A—Doxorubicin—Epirubicin—urinary bladder cancer	0.000187	0.0436	CbGdCrCtD
Sparfloxacin—TOP2A—Idarubicin—Epirubicin—urinary bladder cancer	0.000187	0.0436	CbGdCrCtD
Sparfloxacin—TOP2A—Daunorubicin—Epirubicin—urinary bladder cancer	0.000187	0.0436	CbGdCrCtD
Sparfloxacin—ABCB1—renal system—urinary bladder cancer	0.000186	0.0231	CbGeAlD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000185	0.00772	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000183	0.00767	CbGpPWpGaD
Sparfloxacin—ABCB1—urethra—urinary bladder cancer	0.000183	0.0226	CbGeAlD
Sparfloxacin—TOP2A—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000173	0.0403	CbGdCrCtD
Sparfloxacin—TOP2A—Idarubicin—Doxorubicin—urinary bladder cancer	0.000173	0.0403	CbGdCrCtD
Sparfloxacin—TOP2A—Epirubicin—Doxorubicin—urinary bladder cancer	0.000173	0.0403	CbGdCrCtD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—urinary bladder cancer	0.000169	0.00706	CbGpPWpGaD
Sparfloxacin—TOP2A—Gastric Cancer Network 2—TP53—urinary bladder cancer	0.000164	0.00685	CbGpPWpGaD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00016	0.0067	CbGpPWpGaD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—CCNE1—urinary bladder cancer	0.000155	0.00648	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—ESPL1—urinary bladder cancer	0.000155	0.00647	CbGpPWpGaD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—TYMS—urinary bladder cancer	0.000152	0.00637	CbGpPWpGaD
Sparfloxacin—ABCB1—female reproductive system—urinary bladder cancer	0.000149	0.0185	CbGeAlD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000148	0.00618	CbGpPWpGaD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—RB1—urinary bladder cancer	0.000147	0.00614	CbGpPWpGaD
Sparfloxacin—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	0.000144	0.0337	CbGdCrCtD
Sparfloxacin—TOP2A—Cell Cycle—ESPL1—urinary bladder cancer	0.000138	0.00578	CbGpPWpGaD
Sparfloxacin—ABCB1—vagina—urinary bladder cancer	0.000135	0.0167	CbGeAlD
Sparfloxacin—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.000129	0.00541	CbGpPWpGaD
Sparfloxacin—ABCC2—NRF2 pathway—NQO1—urinary bladder cancer	0.000129	0.0054	CbGpPWpGaD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—CDK4—urinary bladder cancer	0.000119	0.00497	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000117	0.00491	CbGpPWpGaD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000117	0.0049	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	0.000117	0.0049	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	0.000117	0.0049	CbGpPWpGaD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000116	0.00485	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000115	0.00483	CbGpPWpGaD
Sparfloxacin—TOP2A—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000111	0.00463	CbGpPWpGaD
Sparfloxacin—TOP2A—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000109	0.00458	CbGpPWpGaD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	0.000109	0.00456	CbGpPWpGaD
Sparfloxacin—ABCC2—NRF2 pathway—GSTP1—urinary bladder cancer	0.000108	0.00451	CbGpPWpGaD
Sparfloxacin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000107	0.00448	CbGpPWpGaD
Sparfloxacin—Haematuria—Methotrexate—urinary bladder cancer	0.000105	0.000757	CcSEcCtD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	0.000105	0.00441	CbGpPWpGaD
Sparfloxacin—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000105	0.000756	CcSEcCtD
Sparfloxacin—Dyspnoea—Etoposide—urinary bladder cancer	0.000105	0.000754	CcSEcCtD
Sparfloxacin—TOP2A—Cell Cycle—LIG1—urinary bladder cancer	0.000105	0.00438	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—STAG2—urinary bladder cancer	0.000105	0.00438	CbGpPWpGaD
Sparfloxacin—Somnolence—Etoposide—urinary bladder cancer	0.000105	0.000752	CcSEcCtD
Sparfloxacin—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000105	0.000751	CcSEcCtD
Sparfloxacin—Epistaxis—Methotrexate—urinary bladder cancer	0.000104	0.000749	CcSEcCtD
Sparfloxacin—Vomiting—Thiotepa—urinary bladder cancer	0.000104	0.000748	CcSEcCtD
Sparfloxacin—Pneumonia—Epirubicin—urinary bladder cancer	0.000104	0.000748	CcSEcCtD
Sparfloxacin—Rash—Thiotepa—urinary bladder cancer	0.000103	0.000742	CcSEcCtD
Sparfloxacin—Bronchitis—Doxorubicin—urinary bladder cancer	0.000103	0.000742	CcSEcCtD
Sparfloxacin—Dermatitis—Thiotepa—urinary bladder cancer	0.000103	0.000742	CcSEcCtD
Sparfloxacin—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000103	0.000741	CcSEcCtD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	0.000103	0.00432	CbGpPWpGaD
Sparfloxacin—Headache—Thiotepa—urinary bladder cancer	0.000103	0.000737	CcSEcCtD
Sparfloxacin—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000103	0.000737	CcSEcCtD
Sparfloxacin—Decreased appetite—Etoposide—urinary bladder cancer	0.000102	0.000735	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000102	0.00428	CbGpPWpGaD
Sparfloxacin—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000102	0.000732	CcSEcCtD
Sparfloxacin—Body temperature increased—Cisplatin—urinary bladder cancer	0.000102	0.00073	CcSEcCtD
Sparfloxacin—Jaundice—Epirubicin—urinary bladder cancer	0.000101	0.000724	CcSEcCtD
Sparfloxacin—Stomatitis—Epirubicin—urinary bladder cancer	0.000101	0.000724	CcSEcCtD
Sparfloxacin—Pain—Etoposide—urinary bladder cancer	0.000101	0.000723	CcSEcCtD
Sparfloxacin—Constipation—Etoposide—urinary bladder cancer	0.000101	0.000723	CcSEcCtD
Sparfloxacin—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000101	0.000722	CcSEcCtD
Sparfloxacin—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000101	0.000722	CcSEcCtD
Sparfloxacin—Dysuria—Doxorubicin—urinary bladder cancer	0.0001	0.000721	CcSEcCtD
Sparfloxacin—Hypersensitivity—Fluorouracil—urinary bladder cancer	9.99e-05	0.000717	CcSEcCtD
Sparfloxacin—Haemoglobin—Methotrexate—urinary bladder cancer	9.98e-05	0.000717	CcSEcCtD
Sparfloxacin—Hepatitis—Methotrexate—urinary bladder cancer	9.93e-05	0.000713	CcSEcCtD
Sparfloxacin—Haemorrhage—Methotrexate—urinary bladder cancer	9.93e-05	0.000713	CcSEcCtD
Sparfloxacin—Sweating—Epirubicin—urinary bladder cancer	9.93e-05	0.000712	CcSEcCtD
Sparfloxacin—ABCC2—NRF2 pathway—GSTM1—urinary bladder cancer	9.9e-05	0.00414	CbGpPWpGaD
Sparfloxacin—Asthenia—Gemcitabine—urinary bladder cancer	9.9e-05	0.00071	CcSEcCtD
Sparfloxacin—Haematuria—Epirubicin—urinary bladder cancer	9.87e-05	0.000709	CcSEcCtD
Sparfloxacin—Pharyngitis—Methotrexate—urinary bladder cancer	9.86e-05	0.000708	CcSEcCtD
Sparfloxacin—TOP2A—Circadian rythm related genes—FAS—urinary bladder cancer	9.81e-05	0.0041	CbGpPWpGaD
Sparfloxacin—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	9.81e-05	0.000704	CcSEcCtD
Sparfloxacin—Epistaxis—Epirubicin—urinary bladder cancer	9.77e-05	0.000701	CcSEcCtD
Sparfloxacin—Pruritus—Gemcitabine—urinary bladder cancer	9.76e-05	0.000701	CcSEcCtD
Sparfloxacin—Nausea—Thiotepa—urinary bladder cancer	9.74e-05	0.000699	CcSEcCtD
Sparfloxacin—Sinusitis—Epirubicin—urinary bladder cancer	9.71e-05	0.000697	CcSEcCtD
Sparfloxacin—Feeling abnormal—Etoposide—urinary bladder cancer	9.71e-05	0.000697	CcSEcCtD
Sparfloxacin—Agranulocytosis—Epirubicin—urinary bladder cancer	9.66e-05	0.000694	CcSEcCtD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	9.65e-05	0.00404	CbGpPWpGaD
Sparfloxacin—Pneumonia—Doxorubicin—urinary bladder cancer	9.64e-05	0.000692	CcSEcCtD
Sparfloxacin—Gastrointestinal pain—Etoposide—urinary bladder cancer	9.63e-05	0.000691	CcSEcCtD
Sparfloxacin—Pruritus—Fluorouracil—urinary bladder cancer	9.6e-05	0.000689	CcSEcCtD
Sparfloxacin—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	9.5e-05	0.000682	CcSEcCtD
Sparfloxacin—Hypersensitivity—Cisplatin—urinary bladder cancer	9.47e-05	0.00068	CcSEcCtD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	9.44e-05	0.00395	CbGpPWpGaD
Sparfloxacin—Diarrhoea—Gemcitabine—urinary bladder cancer	9.44e-05	0.000678	CcSEcCtD
Sparfloxacin—Erythema multiforme—Methotrexate—urinary bladder cancer	9.39e-05	0.000674	CcSEcCtD
Sparfloxacin—Urticaria—Etoposide—urinary bladder cancer	9.36e-05	0.000672	CcSEcCtD
Sparfloxacin—Haemoglobin—Epirubicin—urinary bladder cancer	9.34e-05	0.000671	CcSEcCtD
Sparfloxacin—Stomatitis—Doxorubicin—urinary bladder cancer	9.34e-05	0.00067	CcSEcCtD
Sparfloxacin—Jaundice—Doxorubicin—urinary bladder cancer	9.34e-05	0.00067	CcSEcCtD
Sparfloxacin—Rhinitis—Epirubicin—urinary bladder cancer	9.32e-05	0.000669	CcSEcCtD
Sparfloxacin—Abdominal pain—Etoposide—urinary bladder cancer	9.31e-05	0.000668	CcSEcCtD
Sparfloxacin—Body temperature increased—Etoposide—urinary bladder cancer	9.31e-05	0.000668	CcSEcCtD
Sparfloxacin—Urinary tract infection—Doxorubicin—urinary bladder cancer	9.31e-05	0.000668	CcSEcCtD
Sparfloxacin—Conjunctivitis—Doxorubicin—urinary bladder cancer	9.31e-05	0.000668	CcSEcCtD
Sparfloxacin—Haemorrhage—Epirubicin—urinary bladder cancer	9.29e-05	0.000667	CcSEcCtD
Sparfloxacin—Hepatitis—Epirubicin—urinary bladder cancer	9.29e-05	0.000667	CcSEcCtD
Sparfloxacin—Diarrhoea—Fluorouracil—urinary bladder cancer	9.28e-05	0.000666	CcSEcCtD
Sparfloxacin—Tinnitus—Methotrexate—urinary bladder cancer	9.26e-05	0.000665	CcSEcCtD
Sparfloxacin—Hypoaesthesia—Epirubicin—urinary bladder cancer	9.25e-05	0.000664	CcSEcCtD
Sparfloxacin—Asthenia—Cisplatin—urinary bladder cancer	9.23e-05	0.000662	CcSEcCtD
Sparfloxacin—Pharyngitis—Epirubicin—urinary bladder cancer	9.22e-05	0.000662	CcSEcCtD
Sparfloxacin—Sweating—Doxorubicin—urinary bladder cancer	9.18e-05	0.000659	CcSEcCtD
Sparfloxacin—Oedema peripheral—Epirubicin—urinary bladder cancer	9.16e-05	0.000657	CcSEcCtD
Sparfloxacin—Haematuria—Doxorubicin—urinary bladder cancer	9.13e-05	0.000656	CcSEcCtD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	9.07e-05	0.0038	CbGpPWpGaD
Sparfloxacin—Epistaxis—Doxorubicin—urinary bladder cancer	9.04e-05	0.000649	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	9.03e-05	0.00378	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	8.99e-05	0.00376	CbGpPWpGaD
Sparfloxacin—Sinusitis—Doxorubicin—urinary bladder cancer	8.99e-05	0.000645	CcSEcCtD
Sparfloxacin—Dizziness—Fluorouracil—urinary bladder cancer	8.97e-05	0.000644	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	8.96e-05	0.00375	CbGpPWpGaD
Sparfloxacin—Agranulocytosis—Doxorubicin—urinary bladder cancer	8.94e-05	0.000642	CcSEcCtD
Sparfloxacin—Chills—Methotrexate—urinary bladder cancer	8.91e-05	0.00064	CcSEcCtD
Sparfloxacin—Diarrhoea—Cisplatin—urinary bladder cancer	8.8e-05	0.000632	CcSEcCtD
Sparfloxacin—Erythema multiforme—Epirubicin—urinary bladder cancer	8.79e-05	0.000631	CcSEcCtD
Sparfloxacin—Alopecia—Methotrexate—urinary bladder cancer	8.78e-05	0.00063	CcSEcCtD
Sparfloxacin—Vomiting—Gemcitabine—urinary bladder cancer	8.77e-05	0.00063	CcSEcCtD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	8.74e-05	0.00366	CbGpPWpGaD
Sparfloxacin—ABCB1—lymph node—urinary bladder cancer	8.71e-05	0.0108	CbGeAlD
Sparfloxacin—Rash—Gemcitabine—urinary bladder cancer	8.7e-05	0.000624	CcSEcCtD
Sparfloxacin—Dermatitis—Gemcitabine—urinary bladder cancer	8.69e-05	0.000624	CcSEcCtD
Sparfloxacin—Hypersensitivity—Etoposide—urinary bladder cancer	8.68e-05	0.000623	CcSEcCtD
Sparfloxacin—Tinnitus—Epirubicin—urinary bladder cancer	8.67e-05	0.000622	CcSEcCtD
Sparfloxacin—Haemoglobin—Doxorubicin—urinary bladder cancer	8.64e-05	0.00062	CcSEcCtD
Sparfloxacin—Headache—Gemcitabine—urinary bladder cancer	8.64e-05	0.00062	CcSEcCtD
Sparfloxacin—TOP2A—Circadian rythm related genes—CDK4—urinary bladder cancer	8.63e-05	0.00361	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—RRM2—urinary bladder cancer	8.63e-05	0.00361	CbGpPWpGaD
Sparfloxacin—Vomiting—Fluorouracil—urinary bladder cancer	8.62e-05	0.000619	CcSEcCtD
Sparfloxacin—Rhinitis—Doxorubicin—urinary bladder cancer	8.62e-05	0.000619	CcSEcCtD
Sparfloxacin—Hepatitis—Doxorubicin—urinary bladder cancer	8.6e-05	0.000617	CcSEcCtD
Sparfloxacin—Haemorrhage—Doxorubicin—urinary bladder cancer	8.6e-05	0.000617	CcSEcCtD
Sparfloxacin—Hypoaesthesia—Doxorubicin—urinary bladder cancer	8.56e-05	0.000614	CcSEcCtD
Sparfloxacin—Rash—Fluorouracil—urinary bladder cancer	8.55e-05	0.000614	CcSEcCtD
Sparfloxacin—Dermatitis—Fluorouracil—urinary bladder cancer	8.54e-05	0.000613	CcSEcCtD
Sparfloxacin—Pharyngitis—Doxorubicin—urinary bladder cancer	8.54e-05	0.000613	CcSEcCtD
Sparfloxacin—Headache—Fluorouracil—urinary bladder cancer	8.5e-05	0.00061	CcSEcCtD
Sparfloxacin—Oedema peripheral—Doxorubicin—urinary bladder cancer	8.47e-05	0.000608	CcSEcCtD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	8.47e-05	0.00354	CbGpPWpGaD
Sparfloxacin—Dysgeusia—Methotrexate—urinary bladder cancer	8.47e-05	0.000608	CcSEcCtD
Sparfloxacin—Asthenia—Etoposide—urinary bladder cancer	8.45e-05	0.000607	CcSEcCtD
Sparfloxacin—Back pain—Methotrexate—urinary bladder cancer	8.36e-05	0.0006	CcSEcCtD
Sparfloxacin—Chills—Epirubicin—urinary bladder cancer	8.34e-05	0.000599	CcSEcCtD
Sparfloxacin—Pruritus—Etoposide—urinary bladder cancer	8.33e-05	0.000598	CcSEcCtD
Sparfloxacin—Arrhythmia—Epirubicin—urinary bladder cancer	8.3e-05	0.000596	CcSEcCtD
Sparfloxacin—Alopecia—Epirubicin—urinary bladder cancer	8.21e-05	0.00059	CcSEcCtD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	8.2e-05	0.00343	CbGpPWpGaD
Sparfloxacin—Nausea—Gemcitabine—urinary bladder cancer	8.19e-05	0.000588	CcSEcCtD
Sparfloxacin—Vomiting—Cisplatin—urinary bladder cancer	8.18e-05	0.000587	CcSEcCtD
Sparfloxacin—Erythema multiforme—Doxorubicin—urinary bladder cancer	8.13e-05	0.000584	CcSEcCtD
Sparfloxacin—Rash—Cisplatin—urinary bladder cancer	8.11e-05	0.000582	CcSEcCtD
Sparfloxacin—Dermatitis—Cisplatin—urinary bladder cancer	8.1e-05	0.000581	CcSEcCtD
Sparfloxacin—Diarrhoea—Etoposide—urinary bladder cancer	8.06e-05	0.000579	CcSEcCtD
Sparfloxacin—Nausea—Fluorouracil—urinary bladder cancer	8.06e-05	0.000578	CcSEcCtD
Sparfloxacin—Ill-defined disorder—Methotrexate—urinary bladder cancer	8.02e-05	0.000576	CcSEcCtD
Sparfloxacin—Tinnitus—Doxorubicin—urinary bladder cancer	8.02e-05	0.000576	CcSEcCtD
Sparfloxacin—Flatulence—Epirubicin—urinary bladder cancer	7.97e-05	0.000572	CcSEcCtD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	7.97e-05	0.00333	CbGpPWpGaD
Sparfloxacin—Tension—Epirubicin—urinary bladder cancer	7.94e-05	0.00057	CcSEcCtD
Sparfloxacin—Dysgeusia—Epirubicin—urinary bladder cancer	7.92e-05	0.000569	CcSEcCtD
Sparfloxacin—Nervousness—Epirubicin—urinary bladder cancer	7.86e-05	0.000564	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	7.85e-05	0.00328	CbGpPWpGaD
Sparfloxacin—TOP2A—Circadian rythm related genes—PPARG—urinary bladder cancer	7.84e-05	0.00328	CbGpPWpGaD
Sparfloxacin—Back pain—Epirubicin—urinary bladder cancer	7.83e-05	0.000562	CcSEcCtD
Sparfloxacin—Malaise—Methotrexate—urinary bladder cancer	7.8e-05	0.00056	CcSEcCtD
Sparfloxacin—Dizziness—Etoposide—urinary bladder cancer	7.79e-05	0.000559	CcSEcCtD
Sparfloxacin—Vertigo—Methotrexate—urinary bladder cancer	7.77e-05	0.000558	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	7.75e-05	0.00324	CbGpPWpGaD
Sparfloxacin—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	7.74e-05	0.00324	CbGpPWpGaD
Sparfloxacin—Chills—Doxorubicin—urinary bladder cancer	7.72e-05	0.000554	CcSEcCtD
Sparfloxacin—Arrhythmia—Doxorubicin—urinary bladder cancer	7.68e-05	0.000551	CcSEcCtD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	7.67e-05	0.00321	CbGpPWpGaD
Sparfloxacin—Nausea—Cisplatin—urinary bladder cancer	7.64e-05	0.000548	CcSEcCtD
Sparfloxacin—Alopecia—Doxorubicin—urinary bladder cancer	7.6e-05	0.000546	CcSEcCtD
Sparfloxacin—Cough—Methotrexate—urinary bladder cancer	7.54e-05	0.000542	CcSEcCtD
Sparfloxacin—Ill-defined disorder—Epirubicin—urinary bladder cancer	7.51e-05	0.000539	CcSEcCtD
Sparfloxacin—Convulsion—Methotrexate—urinary bladder cancer	7.49e-05	0.000538	CcSEcCtD
Sparfloxacin—Vomiting—Etoposide—urinary bladder cancer	7.49e-05	0.000538	CcSEcCtD
Sparfloxacin—Agitation—Epirubicin—urinary bladder cancer	7.44e-05	0.000534	CcSEcCtD
Sparfloxacin—Rash—Etoposide—urinary bladder cancer	7.43e-05	0.000533	CcSEcCtD
Sparfloxacin—Dermatitis—Etoposide—urinary bladder cancer	7.42e-05	0.000533	CcSEcCtD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	7.42e-05	0.0031	CbGpPWpGaD
Sparfloxacin—Headache—Etoposide—urinary bladder cancer	7.38e-05	0.00053	CcSEcCtD
Sparfloxacin—Flatulence—Doxorubicin—urinary bladder cancer	7.38e-05	0.00053	CcSEcCtD
Sparfloxacin—Chest pain—Methotrexate—urinary bladder cancer	7.36e-05	0.000528	CcSEcCtD
Sparfloxacin—Arthralgia—Methotrexate—urinary bladder cancer	7.36e-05	0.000528	CcSEcCtD
Sparfloxacin—Myalgia—Methotrexate—urinary bladder cancer	7.36e-05	0.000528	CcSEcCtD
Sparfloxacin—Tension—Doxorubicin—urinary bladder cancer	7.35e-05	0.000527	CcSEcCtD
Sparfloxacin—TOP2A—Cell Cycle—SMC1A—urinary bladder cancer	7.33e-05	0.00307	CbGpPWpGaD
Sparfloxacin—Dysgeusia—Doxorubicin—urinary bladder cancer	7.33e-05	0.000526	CcSEcCtD
Sparfloxacin—Malaise—Epirubicin—urinary bladder cancer	7.3e-05	0.000524	CcSEcCtD
Sparfloxacin—Discomfort—Methotrexate—urinary bladder cancer	7.27e-05	0.000522	CcSEcCtD
Sparfloxacin—Nervousness—Doxorubicin—urinary bladder cancer	7.27e-05	0.000522	CcSEcCtD
Sparfloxacin—Vertigo—Epirubicin—urinary bladder cancer	7.27e-05	0.000522	CcSEcCtD
Sparfloxacin—Back pain—Doxorubicin—urinary bladder cancer	7.24e-05	0.00052	CcSEcCtD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	7.18e-05	0.003	CbGpPWpGaD
Sparfloxacin—Palpitations—Epirubicin—urinary bladder cancer	7.15e-05	0.000513	CcSEcCtD
Sparfloxacin—Confusional state—Methotrexate—urinary bladder cancer	7.11e-05	0.000511	CcSEcCtD
Sparfloxacin—Cough—Epirubicin—urinary bladder cancer	7.06e-05	0.000507	CcSEcCtD
Sparfloxacin—Anaphylactic shock—Methotrexate—urinary bladder cancer	7.06e-05	0.000506	CcSEcCtD
Sparfloxacin—Convulsion—Epirubicin—urinary bladder cancer	7.01e-05	0.000503	CcSEcCtD
Sparfloxacin—Nausea—Etoposide—urinary bladder cancer	7e-05	0.000502	CcSEcCtD
Sparfloxacin—Hypertension—Epirubicin—urinary bladder cancer	6.99e-05	0.000501	CcSEcCtD
Sparfloxacin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	6.95e-05	0.000499	CcSEcCtD
Sparfloxacin—Thrombocytopenia—Methotrexate—urinary bladder cancer	6.91e-05	0.000496	CcSEcCtD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	6.9e-05	0.00289	CbGpPWpGaD
Sparfloxacin—Chest pain—Epirubicin—urinary bladder cancer	6.89e-05	0.000494	CcSEcCtD
Sparfloxacin—Myalgia—Epirubicin—urinary bladder cancer	6.89e-05	0.000494	CcSEcCtD
Sparfloxacin—Arthralgia—Epirubicin—urinary bladder cancer	6.89e-05	0.000494	CcSEcCtD
Sparfloxacin—Agitation—Doxorubicin—urinary bladder cancer	6.88e-05	0.000494	CcSEcCtD
Sparfloxacin—Anxiety—Epirubicin—urinary bladder cancer	6.86e-05	0.000493	CcSEcCtD
Sparfloxacin—Hyperhidrosis—Methotrexate—urinary bladder cancer	6.82e-05	0.00049	CcSEcCtD
Sparfloxacin—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	6.82e-05	0.00285	CbGpPWpGaD
Sparfloxacin—Discomfort—Epirubicin—urinary bladder cancer	6.81e-05	0.000489	CcSEcCtD
Sparfloxacin—Malaise—Doxorubicin—urinary bladder cancer	6.75e-05	0.000485	CcSEcCtD
Sparfloxacin—Dry mouth—Epirubicin—urinary bladder cancer	6.74e-05	0.000484	CcSEcCtD
Sparfloxacin—Vertigo—Doxorubicin—urinary bladder cancer	6.73e-05	0.000483	CcSEcCtD
Sparfloxacin—Anorexia—Methotrexate—urinary bladder cancer	6.73e-05	0.000483	CcSEcCtD
Sparfloxacin—Confusional state—Epirubicin—urinary bladder cancer	6.66e-05	0.000478	CcSEcCtD
Sparfloxacin—Palpitations—Doxorubicin—urinary bladder cancer	6.62e-05	0.000475	CcSEcCtD
Sparfloxacin—Anaphylactic shock—Epirubicin—urinary bladder cancer	6.6e-05	0.000474	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	6.57e-05	0.00275	CbGpPWpGaD
Sparfloxacin—Cough—Doxorubicin—urinary bladder cancer	6.53e-05	0.000469	CcSEcCtD
Sparfloxacin—Convulsion—Doxorubicin—urinary bladder cancer	6.49e-05	0.000466	CcSEcCtD
Sparfloxacin—Thrombocytopenia—Epirubicin—urinary bladder cancer	6.47e-05	0.000464	CcSEcCtD
Sparfloxacin—Hypertension—Doxorubicin—urinary bladder cancer	6.46e-05	0.000464	CcSEcCtD
Sparfloxacin—Tachycardia—Epirubicin—urinary bladder cancer	6.44e-05	0.000463	CcSEcCtD
Sparfloxacin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	6.43e-05	0.000461	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	6.43e-05	0.00269	CbGpPWpGaD
Sparfloxacin—Hyperhidrosis—Epirubicin—urinary bladder cancer	6.38e-05	0.000458	CcSEcCtD
Sparfloxacin—Insomnia—Methotrexate—urinary bladder cancer	6.38e-05	0.000458	CcSEcCtD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.38e-05	0.00267	CbGpPWpGaD
Sparfloxacin—Myalgia—Doxorubicin—urinary bladder cancer	6.37e-05	0.000458	CcSEcCtD
Sparfloxacin—Arthralgia—Doxorubicin—urinary bladder cancer	6.37e-05	0.000458	CcSEcCtD
Sparfloxacin—Chest pain—Doxorubicin—urinary bladder cancer	6.37e-05	0.000458	CcSEcCtD
Sparfloxacin—Anxiety—Doxorubicin—urinary bladder cancer	6.35e-05	0.000456	CcSEcCtD
Sparfloxacin—Paraesthesia—Methotrexate—urinary bladder cancer	6.34e-05	0.000455	CcSEcCtD
Sparfloxacin—Discomfort—Doxorubicin—urinary bladder cancer	6.3e-05	0.000452	CcSEcCtD
Sparfloxacin—Anorexia—Epirubicin—urinary bladder cancer	6.29e-05	0.000452	CcSEcCtD
Sparfloxacin—Dyspnoea—Methotrexate—urinary bladder cancer	6.29e-05	0.000452	CcSEcCtD
Sparfloxacin—Somnolence—Methotrexate—urinary bladder cancer	6.27e-05	0.00045	CcSEcCtD
Sparfloxacin—Dry mouth—Doxorubicin—urinary bladder cancer	6.23e-05	0.000447	CcSEcCtD
Sparfloxacin—Dyspepsia—Methotrexate—urinary bladder cancer	6.21e-05	0.000446	CcSEcCtD
Sparfloxacin—Confusional state—Doxorubicin—urinary bladder cancer	6.16e-05	0.000442	CcSEcCtD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	6.15e-05	0.00257	CbGpPWpGaD
Sparfloxacin—Decreased appetite—Methotrexate—urinary bladder cancer	6.13e-05	0.00044	CcSEcCtD
Sparfloxacin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	6.11e-05	0.000439	CcSEcCtD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	6.08e-05	0.00254	CbGpPWpGaD
Sparfloxacin—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	6.05e-05	0.00253	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	6.04e-05	0.00253	CbGpPWpGaD
Sparfloxacin—Pain—Methotrexate—urinary bladder cancer	6.03e-05	0.000433	CcSEcCtD
Sparfloxacin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	6.02e-05	0.000432	CcSEcCtD
Sparfloxacin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	5.98e-05	0.000429	CcSEcCtD
Sparfloxacin—Insomnia—Epirubicin—urinary bladder cancer	5.97e-05	0.000429	CcSEcCtD
Sparfloxacin—Tachycardia—Doxorubicin—urinary bladder cancer	5.96e-05	0.000428	CcSEcCtD
Sparfloxacin—Paraesthesia—Epirubicin—urinary bladder cancer	5.93e-05	0.000426	CcSEcCtD
Sparfloxacin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	5.91e-05	0.000424	CcSEcCtD
Sparfloxacin—Dyspnoea—Epirubicin—urinary bladder cancer	5.89e-05	0.000423	CcSEcCtD
Sparfloxacin—Somnolence—Epirubicin—urinary bladder cancer	5.87e-05	0.000421	CcSEcCtD
Sparfloxacin—Anorexia—Doxorubicin—urinary bladder cancer	5.82e-05	0.000418	CcSEcCtD
Sparfloxacin—Feeling abnormal—Methotrexate—urinary bladder cancer	5.81e-05	0.000417	CcSEcCtD
Sparfloxacin—Dyspepsia—Epirubicin—urinary bladder cancer	5.81e-05	0.000417	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	5.81e-05	0.00243	CbGpPWpGaD
Sparfloxacin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5.77e-05	0.000414	CcSEcCtD
Sparfloxacin—Decreased appetite—Epirubicin—urinary bladder cancer	5.74e-05	0.000412	CcSEcCtD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	5.69e-05	0.00238	CbGpPWpGaD
Sparfloxacin—Pain—Epirubicin—urinary bladder cancer	5.65e-05	0.000405	CcSEcCtD
Sparfloxacin—Constipation—Epirubicin—urinary bladder cancer	5.65e-05	0.000405	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.62e-05	0.00235	CbGpPWpGaD
Sparfloxacin—Urticaria—Methotrexate—urinary bladder cancer	5.61e-05	0.000402	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.61e-05	0.00234	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	5.58e-05	0.00234	CbGpPWpGaD
Sparfloxacin—Body temperature increased—Methotrexate—urinary bladder cancer	5.58e-05	0.0004	CcSEcCtD
Sparfloxacin—Abdominal pain—Methotrexate—urinary bladder cancer	5.58e-05	0.0004	CcSEcCtD
Sparfloxacin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.57e-05	0.0004	CcSEcCtD
Sparfloxacin—Insomnia—Doxorubicin—urinary bladder cancer	5.53e-05	0.000397	CcSEcCtD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	5.51e-05	0.0023	CbGpPWpGaD
Sparfloxacin—Paraesthesia—Doxorubicin—urinary bladder cancer	5.49e-05	0.000394	CcSEcCtD
Sparfloxacin—Dyspnoea—Doxorubicin—urinary bladder cancer	5.45e-05	0.000391	CcSEcCtD
Sparfloxacin—Feeling abnormal—Epirubicin—urinary bladder cancer	5.44e-05	0.000391	CcSEcCtD
Sparfloxacin—Somnolence—Doxorubicin—urinary bladder cancer	5.43e-05	0.00039	CcSEcCtD
Sparfloxacin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.4e-05	0.000388	CcSEcCtD
Sparfloxacin—TOP2A—Circadian rythm related genes—PTEN—urinary bladder cancer	5.38e-05	0.00225	CbGpPWpGaD
Sparfloxacin—Dyspepsia—Doxorubicin—urinary bladder cancer	5.38e-05	0.000386	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	5.35e-05	0.00224	CbGpPWpGaD
Sparfloxacin—Decreased appetite—Doxorubicin—urinary bladder cancer	5.31e-05	0.000381	CcSEcCtD
Sparfloxacin—Urticaria—Epirubicin—urinary bladder cancer	5.25e-05	0.000377	CcSEcCtD
Sparfloxacin—Pain—Doxorubicin—urinary bladder cancer	5.22e-05	0.000375	CcSEcCtD
Sparfloxacin—Constipation—Doxorubicin—urinary bladder cancer	5.22e-05	0.000375	CcSEcCtD
Sparfloxacin—Body temperature increased—Epirubicin—urinary bladder cancer	5.22e-05	0.000375	CcSEcCtD
Sparfloxacin—Abdominal pain—Epirubicin—urinary bladder cancer	5.22e-05	0.000375	CcSEcCtD
Sparfloxacin—Hypersensitivity—Methotrexate—urinary bladder cancer	5.2e-05	0.000373	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	5.2e-05	0.00217	CbGpPWpGaD
Sparfloxacin—TOP2A—Circadian rythm related genes—EP300—urinary bladder cancer	5.13e-05	0.00215	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—CCNE1—urinary bladder cancer	5.08e-05	0.00213	CbGpPWpGaD
Sparfloxacin—Asthenia—Methotrexate—urinary bladder cancer	5.06e-05	0.000363	CcSEcCtD
Sparfloxacin—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.03e-05	0.000361	CcSEcCtD
Sparfloxacin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5e-05	0.000359	CcSEcCtD
Sparfloxacin—TOP2A—Cell Cycle—TYMS—urinary bladder cancer	4.99e-05	0.00209	CbGpPWpGaD
Sparfloxacin—Pruritus—Methotrexate—urinary bladder cancer	4.99e-05	0.000358	CcSEcCtD
Sparfloxacin—Hypersensitivity—Epirubicin—urinary bladder cancer	4.86e-05	0.000349	CcSEcCtD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	4.86e-05	0.00203	CbGpPWpGaD
Sparfloxacin—Urticaria—Doxorubicin—urinary bladder cancer	4.85e-05	0.000348	CcSEcCtD
Sparfloxacin—Abdominal pain—Doxorubicin—urinary bladder cancer	4.83e-05	0.000347	CcSEcCtD
Sparfloxacin—Body temperature increased—Doxorubicin—urinary bladder cancer	4.83e-05	0.000347	CcSEcCtD
Sparfloxacin—Diarrhoea—Methotrexate—urinary bladder cancer	4.83e-05	0.000347	CcSEcCtD
Sparfloxacin—Asthenia—Epirubicin—urinary bladder cancer	4.74e-05	0.00034	CcSEcCtD
Sparfloxacin—Pruritus—Epirubicin—urinary bladder cancer	4.67e-05	0.000335	CcSEcCtD
Sparfloxacin—Dizziness—Methotrexate—urinary bladder cancer	4.67e-05	0.000335	CcSEcCtD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.66e-05	0.00195	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.66e-05	0.00195	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.56e-05	0.00191	CbGpPWpGaD
Sparfloxacin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	4.55e-05	0.00191	CbGpPWpGaD
Sparfloxacin—Diarrhoea—Epirubicin—urinary bladder cancer	4.52e-05	0.000324	CcSEcCtD
Sparfloxacin—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.5e-05	0.000323	CcSEcCtD
Sparfloxacin—Vomiting—Methotrexate—urinary bladder cancer	4.49e-05	0.000322	CcSEcCtD
Sparfloxacin—Rash—Methotrexate—urinary bladder cancer	4.45e-05	0.000319	CcSEcCtD
Sparfloxacin—Dermatitis—Methotrexate—urinary bladder cancer	4.44e-05	0.000319	CcSEcCtD
Sparfloxacin—Headache—Methotrexate—urinary bladder cancer	4.42e-05	0.000317	CcSEcCtD
Sparfloxacin—Asthenia—Doxorubicin—urinary bladder cancer	4.38e-05	0.000315	CcSEcCtD
Sparfloxacin—Dizziness—Epirubicin—urinary bladder cancer	4.37e-05	0.000313	CcSEcCtD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	4.35e-05	0.00182	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—TERT—urinary bladder cancer	4.35e-05	0.00182	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	4.34e-05	0.00182	CbGpPWpGaD
Sparfloxacin—Pruritus—Doxorubicin—urinary bladder cancer	4.32e-05	0.00031	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	4.3e-05	0.0018	CbGpPWpGaD
Sparfloxacin—Vomiting—Epirubicin—urinary bladder cancer	4.2e-05	0.000301	CcSEcCtD
Sparfloxacin—Nausea—Methotrexate—urinary bladder cancer	4.19e-05	0.000301	CcSEcCtD
Sparfloxacin—Diarrhoea—Doxorubicin—urinary bladder cancer	4.18e-05	0.0003	CcSEcCtD
Sparfloxacin—Rash—Epirubicin—urinary bladder cancer	4.16e-05	0.000299	CcSEcCtD
Sparfloxacin—Dermatitis—Epirubicin—urinary bladder cancer	4.16e-05	0.000299	CcSEcCtD
Sparfloxacin—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	4.16e-05	0.00174	CbGpPWpGaD
Sparfloxacin—Headache—Epirubicin—urinary bladder cancer	4.14e-05	0.000297	CcSEcCtD
Sparfloxacin—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	4.12e-05	0.00172	CbGpPWpGaD
Sparfloxacin—Dizziness—Doxorubicin—urinary bladder cancer	4.04e-05	0.00029	CcSEcCtD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	3.98e-05	0.00167	CbGpPWpGaD
Sparfloxacin—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	3.97e-05	0.00166	CbGpPWpGaD
Sparfloxacin—Nausea—Epirubicin—urinary bladder cancer	3.92e-05	0.000282	CcSEcCtD
Sparfloxacin—TOP2A—Cell Cycle—ATM—urinary bladder cancer	3.91e-05	0.00164	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—CDK4—urinary bladder cancer	3.89e-05	0.00163	CbGpPWpGaD
Sparfloxacin—Vomiting—Doxorubicin—urinary bladder cancer	3.88e-05	0.000279	CcSEcCtD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	3.87e-05	0.00162	CbGpPWpGaD
Sparfloxacin—Rash—Doxorubicin—urinary bladder cancer	3.85e-05	0.000277	CcSEcCtD
Sparfloxacin—Dermatitis—Doxorubicin—urinary bladder cancer	3.85e-05	0.000276	CcSEcCtD
Sparfloxacin—Headache—Doxorubicin—urinary bladder cancer	3.83e-05	0.000275	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.83e-05	0.0016	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	3.8e-05	0.00159	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—RB1—urinary bladder cancer	3.79e-05	0.00158	CbGpPWpGaD
Sparfloxacin—TOP2A—Circadian rythm related genes—TP53—urinary bladder cancer	3.67e-05	0.00154	CbGpPWpGaD
Sparfloxacin—Nausea—Doxorubicin—urinary bladder cancer	3.63e-05	0.000261	CcSEcCtD
Sparfloxacin—TOP2A—Cell Cycle—RB1—urinary bladder cancer	3.38e-05	0.00142	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	3.37e-05	0.00141	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	3.33e-05	0.00139	CbGpPWpGaD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	3.25e-05	0.00136	CbGpPWpGaD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.99e-05	0.00125	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—CDKN2A—urinary bladder cancer	2.98e-05	0.00124	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.97e-05	0.00124	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.96e-05	0.00124	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.95e-05	0.00123	CbGpPWpGaD
Sparfloxacin—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	2.9e-05	0.00121	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	2.81e-05	0.00118	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	2.72e-05	0.00114	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	2.72e-05	0.00114	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	2.59e-05	0.00108	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.58e-05	0.00108	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—NAT1—urinary bladder cancer	2.58e-05	0.00108	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—GSTO2—urinary bladder cancer	2.58e-05	0.00108	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.55e-05	0.00107	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—CCND1—urinary bladder cancer	2.51e-05	0.00105	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—CDKN1A—urinary bladder cancer	2.43e-05	0.00102	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	2.36e-05	0.000987	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—EP300—urinary bladder cancer	2.31e-05	0.000968	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	2.25e-05	0.000943	CbGpPWpGaD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.19e-05	0.000917	CbGpPWpGaD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.18e-05	0.000913	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.16e-05	0.000905	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	2.12e-05	0.000889	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	2.12e-05	0.000885	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—MYC—urinary bladder cancer	2.02e-05	0.000844	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	2.01e-05	0.000839	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.96e-05	0.000818	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.91e-05	0.0008	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.85e-05	0.000774	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.85e-05	0.000772	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.76e-05	0.000736	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.71e-05	0.000716	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—TP53—urinary bladder cancer	1.66e-05	0.000693	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.56e-05	0.000654	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.53e-05	0.000642	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.5e-05	0.000628	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.43e-05	0.000598	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.42e-05	0.000593	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.41e-05	0.000591	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.26e-05	0.000527	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.22e-05	0.00051	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.13e-05	0.000473	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.13e-05	0.000473	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.1e-05	0.000459	CbGpPWpGaD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.03e-05	0.000429	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—NQO1—urinary bladder cancer	9.11e-06	0.000381	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—GSTP1—urinary bladder cancer	7.6e-06	0.000318	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—TYMS—urinary bladder cancer	7.06e-06	0.000295	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—GSTM1—urinary bladder cancer	6.98e-06	0.000292	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—NCOR1—urinary bladder cancer	6.98e-06	0.000292	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—GPX1—urinary bladder cancer	6.69e-06	0.00028	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—ERCC2—urinary bladder cancer	6.56e-06	0.000275	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—MTHFR—urinary bladder cancer	6.17e-06	0.000258	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—PPARG—urinary bladder cancer	5e-06	0.000209	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—CREBBP—urinary bladder cancer	4.81e-06	0.000201	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—PTGS2—urinary bladder cancer	3.94e-06	0.000165	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—PTEN—urinary bladder cancer	3.43e-06	0.000144	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—EP300—urinary bladder cancer	3.27e-06	0.000137	CbGpPWpGaD
